Industry Investment Rating - The industry investment rating is maintained at "Outperform" [2] Core Insights - The report highlights a recovery in overseas CXO orders, with optimistic guidance for 2026. The CDMO sector shows strong performance, while clinical CROs face challenges but are showing signs of improvement in orders [5][6][14] - The report emphasizes the differentiation in performance among companies, with CDMO firms like Lonza and Bachem demonstrating robust growth, while some clinical CROs like Fortrea and Charles River Laboratories are under pressure [14][15] - The report suggests a cautious yet optimistic outlook for the industry, with CDMO companies maintaining high capital expenditure and expanding capacity in emerging drug types such as ADCs, peptides, and oligonucleotides [25][28] Summary by Sections 1. Overseas CXO Orders Recovery and 2026 Guidance - The CXO industry shows a mixed performance in 2025, with CDMO companies exhibiting strong profitability growth, while clinical CROs face demand fluctuations and cost pressures [14] - Companies like Lonza and Bachem report significant revenue growth, driven by strong demand for their platforms [14][15] - There are positive signals in order performance, particularly in the second half of 2025, indicating a recovery in global biopharmaceutical investment [17][19] 2. Industry Views and Investment Recommendations - The report notes a downward trend in the A-share pharmaceutical sector, with a 2.77% decline, underperforming the CSI 300 index [32] - The innovative drug sector is experiencing a rebound, with increasing confidence in the competitiveness of domestic innovative drugs, supported by clinical data from key projects [36] - The report suggests focusing on investment opportunities in high-growth areas such as high-end imaging, surgical robots, and AI-driven medical devices [8] 3. Market Performance - The report details the performance of various sub-sectors within the pharmaceutical industry, highlighting the outperformance of the in vitro diagnostics sector and the underperformance of the hospital sector [7][32] - The report provides insights into the valuation changes across different pharmaceutical sub-industries, indicating a need for strategic investment in sectors showing resilience and growth potential [10][11]

18 March 2026 | 8:14PM HKT Equity Research China Healthcare: Medical Device & Services: 4Q/2H25 preview: CDMO Order Momentum in Focus; Devices & Services Await Clear Recovery In this note, we present our 4Q25 preview for our China Medical Device & Services coverage. There are no changes to our estimates, TPs, investment theses and ratings. CDMO: Focus shifting to backlog, FY26 guidance and durability of the cycle n With most major CDMO names having already reported preliminary results (see our note), invest ...

Summary of Key Points from Conference Call Records Industry or Company Involved - The conference call discusses the "15th Five-Year Plan" (十五五规划) and its implications across various industries including service consumption, biomedicine, home appliances, construction materials, power and environmental protection, and semiconductors. Core Insights and Arguments Service Consumption - The "15th Five-Year Plan" positions service consumption as a key driver of domestic demand due to its lack of quantity constraints and a higher leverage effect (1:10) compared to durable goods (1:3) [1][6] - The travel industry, outdoor sports, and the silver economy are highlighted as significant areas for investment [1] Biomedicine - Biomedicine is elevated to a new pillar industry, focusing on original innovation, biomanufacturing, and brain-machine interfaces, with a target output of 5 trillion yuan [1][11] - Investment opportunities are identified in areas such as dual antibodies, ADCs, synthetic biology, and AI in pharmaceuticals [1][11] Home Appliances - The home appliance sector shows resilience, with leading companies like Midea, Gree, and Haier benefiting from policies favoring offline channels [1][8] - TCL Electronics is noted for its potential profitability and high dividend yield following its integration with Sony's business [1][9] Construction and Building Materials - The construction materials sector is shifting towards stock operation and smart technology, with coal chemical and green energy becoming core growth areas [1][13] - Investment in coal chemical is expected to rise from 20 billion to a peak of 100 billion yuan [1][14] Power and Environmental Protection - The plan includes nuclear fusion as a future industry and emphasizes the need for new data centers to consume over 80% green electricity, benefiting solar and energy storage sectors [1][18] Semiconductors - The semiconductor industry is focusing on advanced process expansion and domestic production of photoresists, with key companies like Northern Huachuang and Zhongwei being highlighted [1][19] Other Important but Possibly Overlooked Content - The plan emphasizes the importance of digital transformation in various sectors, including the integration of digital economy with traditional industries [4] - The focus on high-quality development in the express delivery industry suggests a shift from volume to revenue growth, indicating potential price increases and improved profitability [12] - The construction industry is expected to undergo significant changes, with a focus on smart manufacturing and green production, which may alter competitive dynamics [16][17] - The "anti-involution" strategy aims to regulate capacity and promote profit-oriented growth in the construction and building materials sectors, potentially leading to a more sustainable industry environment [17] This summary encapsulates the key insights and implications of the "15th Five-Year Plan" across various industries, highlighting potential investment opportunities and strategic shifts.

Core Viewpoint - The innovative drug sector has reached a stage where it is largely ignored by the market, despite positive changes in company fundamentals and a significant increase in the number of licensing deals [3][4][5]. Group 1: Historical Context of the Innovative Drug Sector - The current market cycle for innovative drugs has transitioned from a period of significant valuation decline to a recovery phase, with many companies' valuations hitting historical lows [6][7]. - A clear turning point in fundamentals was observed in early 2025, with a shift from a model reliant on continuous funding for R&D to one focused on revenue generation from product sales and improved cash flow [7]. - The number of licensing deals in China surged to approximately 157, with a total value exceeding $130 billion, more than doubling from the previous year, indicating a strong presence in the global business development market [7][8]. Group 2: Recent Market Adjustments - From September 2025 to February 2026, many companies experienced a market correction of around 30%, primarily driven by funding issues and external market conditions rather than fundamental industry problems [9][10]. - The disconnect between industry progress and stock price performance is evident, with the sector experiencing a typical "good industry + temporary negative sentiment" scenario [11]. Group 3: Comparison with Previous Market Cycles - The current phase (2025 onwards) differs significantly from the previous cycle (2018-2020), which was characterized by domestic institutional benefits and valuation discovery, with many companies still in early clinical stages [12][13]. - In contrast, the current cycle features companies that have advanced to leading positions in certain therapeutic areas, with a notable increase in the global market share of Chinese innovative drugs [13][14]. Group 4: Future Outlook for 2026 - The year 2026 is anticipated to be pivotal, with a shift from speculative valuations to a focus on actual data and cash flow, as companies like BeiGene are expected to achieve significant profitability [15][16]. - Key clinical milestones for several major drugs are expected in 2026, which will serve as critical tests for their global market potential [17][18]. Group 5: Market Trends and Opportunities - The global innovative drug market is projected to grow at a compound annual growth rate (CAGR) approaching double digits, potentially exceeding $1 trillion by 2030, with the Chinese market expected to reach approximately $100 billion by 2025 [21][22]. - The role of Chinese innovative drugs in the global supply chain is evolving from a passive participant to a significant contributor, with increasing procurement from multinational pharmaceutical companies [22][23]. Group 6: Catalysts for Market Recovery - The market is currently in a phase of adjustment, with a need for a catalyst to realign value perceptions, which could come from significant clinical data releases at major conferences or a shift in investor focus back to innovative drugs [24][25]. - The emergence of a landmark drug achieving global market entry and pricing could significantly uplift the sector's overall valuation [26].

Core Viewpoint - The pharmaceutical sector, characterized by both technology and consumer attributes, is expected to continue exhibiting structural trends amid market fluctuations, with a focus on innovative drug segments and emerging technologies like AI in healthcare [1][2]. Group 1: Market Performance - The Shanghai and Shenzhen 300 index rose by 0.36%, while the pharmaceutical and biological sector declined by 0.81%, ranking 21st among 31 primary sub-industries [2][4]. - The medical services sector increased by 0.22%, while chemical pharmaceuticals, biological products, medical devices, traditional Chinese medicine, and pharmaceutical commerce saw declines of 0.54%, 0.89%, 1.07%, 1.75%, and 2.68% respectively [2][4]. Group 2: Investment Recommendations - Companies are advised to focus on sectors with positive fundamental changes and light institutional holdings, particularly in the AI healthcare and small nucleic acid segments, which have shown strong performance [2][3]. - The report suggests monitoring companies that are not primarily in the pharmaceutical/medical AI+ sector but are actively adopting related technologies with potential for short-term valuation flexibility [2]. Group 3: In Vivo CAR Developments - Multiple clinical studies for in vivo CAR are expected to reach major endpoints within the year, particularly those targeting autoimmune indications, indicating significant potential for this cutting-edge technology [3][4]. - Abbvie's acquisition of Capstan for $21 billion is highlighted, with its core pipeline expected to reach major clinical endpoints soon, focusing on safety and immune response indicators, which could pave the way for further development in autoimmune indications [4]. Group 4: Overall Sector Analysis - The pharmaceutical sector has yielded a return of 2.44% since early 2026, outperforming the Shanghai and Shenzhen 300 index by 1.79 percentage points [4].

Core Insights - The article discusses the significant growth of China's innovative pharmaceuticals, projecting a cross-border transaction value exceeding $136 billion by 2025, marking a shift from "single-point innovation" to "global value supply" [2] - The event aims to analyze the latest trends in cross-border licensing and M&A transactions, focusing on the ADC and oncology asset export logic, as well as the competitive landscape in the commercialization of the GLP-1 sector [2] - The article highlights the importance of regulatory updates and the transformative potential of artificial intelligence in drug development, pipeline efficiency, and valuation frameworks [2] Group 1: Event Overview - The Bloomberg Pharmaceutical Market Insight Conference will take place on March 10, 2026, in Shanghai, focusing on the reshaping of valuation systems as China's pipeline becomes a core market driver [2] - The agenda includes keynote speeches, panel discussions on future M&A technology routes, and interactive exchanges with industry leaders and Bloomberg experts [3] Group 2: Key Speakers - Notable speakers include executives from major companies such as China Biopharmaceutical Co., Morgan Stanley, and Insilico Medicine, indicating a diverse representation of industry expertise [4]

Core Insights - The article discusses the insights from Yang Yunxia, a partner at Sequoia China, highlighting that China's biopharmaceutical innovation has become a significant player in the global industry and a source of world innovation [3][6]. Group 1: Market Trends and Investment Directions - The biopharmaceutical sector in China is expected to continue its growth, with a focus on major disease areas such as oncology, autoimmune diseases, neurology, and metabolism, while also addressing underrepresented fields like gynecology, nephrology, and ophthalmology [3][8]. - The transaction value of Chinese innovative drug business development (BD) has increased tenfold over the past five years, indicating a growing recognition and willingness of multinational corporations (MNCs) to pay premiums for Chinese assets [3][9]. - The market is experiencing a resurgence, with increased enthusiasm from early-stage entrepreneurs and active participation from investors, making 2025 a fruitful year for the industry [5][6]. Group 2: Product Development and Innovation - There is an ongoing evolution in drug molecular forms, with advancements expected in antibody-drug conjugates (ADCs) and small nucleic acids, moving towards dual-target and dual-toxin formats [3][8]. - The trend of Chinese innovative drugs gaining international recognition is anticipated to continue, with more overseas companies showing interest in Chinese assets and establishing collaborations with local investment institutions [9][10]. Group 3: Future Outlook and Strategic Focus - The investment strategy of Sequoia China remains consistent, focusing on innovation and maintaining long-term relationships with early-stage companies and entrepreneurs [7][10]. - The expectation for 2026 is to see more entrepreneurs with a global perspective and competitive products entering the market, reflecting a shift in focus towards genuine global innovation [11].

Company and Industry Summary Company: WuXi Biologics Key Points - **High Growth in Dual Antibody and ADC**: WuXi Biologics is experiencing rapid growth in dual antibodies (双多抗) and antibody-drug conjugates (ADC), with a significant market share that positions the company to potentially outperform in new molecular tracks [1][1] - **Revenue Contribution**: Dual antibodies currently contribute nearly 20% of the group's revenue, with a year-on-year growth exceeding 120% [1][1] - **Project Pipeline**: In 2025, two-thirds of the new projects signed by the company will be in dual antibodies and ADC, with approximately half of these projects originating from the United States [1][1] - **ADC Projects**: The company has a total of 252 ADC projects, indicating a sustained upward trend in market conditions for this segment [1][1] - **Market Share in Dual Antibodies**: WuXi Biologics holds a market share of over 55% in the dual antibody domain, with expectations for the M-end to release growth potential as project conversion progresses [1][1] - **Record Project Numbers**: The company is set to achieve a record number of projects in 2025, with a significant increase in PPQ (Process Performance Qualification) projects [1][1] - **Total Projects**: By the end of 2025, the total number of projects is expected to reach 945, including 74 in Phase 3 clinical trials and 25 commercial projects [1][1] - **PPQ Projects Timeline**: The company plans to complete 28 PPQ projects in 2025 and has scheduled 34 PPQ projects for 2026, indicating a continuous increase in project activity [2][2] - **Commercialization Timeline**: It is estimated that it takes about two years from PPQ to commercial production, with the M-end's commercialization potential expected to accelerate post-2027 [2][2] - **Revenue and Profit Forecast**: Projected revenues for 2025, 2026, and 2027 are estimated at 21.79 billion, 25.92 billion, and 31.02 billion yuan respectively, with adjusted net profits of 5.71 billion, 6.94 billion, and 8.49 billion yuan [2][2] - **Valuation Metrics**: Corresponding valuations based on current market capitalization are projected to be 28x, 23x, and 19x for the years 2025, 2026, and 2027 respectively [2][2] Risk Factors - **Geopolitical Risks**: The company faces potential geopolitical risks that could impact operations and market performance [3][3] - **Sales Performance Risks**: There is a risk that the sales of commercialized products may not meet expectations [3][3]

Core Viewpoint - The innovation logic of the biopharmaceutical industry is undergoing adjustments due to intensified global competition, evolving technology platforms, and changing capital and regulatory environments. Systematic innovation capability and translational efficiency are becoming key factors influencing the industry's sustainable output [2]. Event Overview - The third Global Biopharmaceutical Conference 2026 will be held on April 16, 2026, at the Zhongguancun Conference Center, aiming to connect research, clinical, corporate, capital, and regulatory aspects of biopharmaceutical innovation [2][19]. - The conference will feature three main components: the release of a white paper, award evaluations, and multi-theme forums, presenting a comprehensive view of the global biopharmaceutical innovation ecosystem and development trends [2][9]. White Paper Release - The conference will officially release the "2026 Global Biopharmaceutical Innovation White Paper," focusing on technology evolution, product pipeline layout, corporate development paths, and changes in industry structure, providing valuable industry observation frameworks for enterprises, investors, and industry practitioners [9][10]. - The white paper serves as a significant window for companies to showcase their technological platform capabilities, research depth, and industry positioning [10]. Award Evaluation - The conference will announce multiple annual awards evaluating various dimensions of biopharmaceutical innovation, emphasizing long-term innovation capabilities rather than short-term market performance [11][12]. - Categories for awards include Annual Biopharmaceutical Innovation Enterprise, Annual Innovative Drug Product Award, Annual Technology Platform Innovation Award, and Annual Clinical Translation Innovation Award [15]. Multi-Theme Forums - The forums will address high-interest and collaborative potential topics in the biopharmaceutical industry, including trends in innovative drug development, antibody and ADC technologies, cell and gene therapy frontiers, nucleic acid drugs and delivery technologies, and biopharmaceutical innovation commercialization discussions [13][14]. - The forums aim to create a multi-perspective dialogue system involving various industry roles, enhancing collaboration and knowledge sharing [16]. Audience Composition - The conference targets a diverse audience, including research and clinical experts, biopharmaceutical company R&D and management teams, industry observers, investment institution representatives, and experts in registration, regulation, and payment [18][20]. - The event is positioned as an industry-focused, research-oriented, and systematic conference rather than a purely academic or promotional meeting [18].

Core Viewpoint - Fuhong Hanlin (2696.HK) has seen a significant stock price increase of over 8% on February 10, with a total rise of 30% over six days, indicating a reversal trend and a current market value of HKD 39.6 billion [1] Group 1: Company Developments - Fuhong Hanlin has completed the full circulation of H-shares, which is expected to enhance its global strategy and attract more international investors, benefiting long-term development and shareholder interests [1] - At the JPM 2026 conference, the company showcased its "Globalization 2.0" strategy, outlining future innovation pipeline and development plans, with over 40 new clinical research applications expected to be approved in the next five years [1] - By 2030, the company anticipates having over 20 products launched globally, with 15 expected to enter the European and American markets [1] Group 2: Product Pipeline and Collaborations - The company plans to commercialize more Antibody-Drug Conjugates (ADCs), bispecific antibodies, and T-cell engagers (TCEs), targeting four major therapeutic areas: oncology, autoimmune diseases, metabolism, and central nervous system disorders [1] - Fuhong Hanlin has entered into an exclusive commercialization agreement with Eisai Co., Ltd. for the anti-PD-1 antibody, Surulitinib, in the Japanese market, which includes an upfront payment of USD 75 million and potential milestone payments totaling up to USD 800.1 million, along with royalties based on product sales [1]